Dr. Kurie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1992
Medical College of GeorgiaResidency, Internal Medicine, 1983 - 1986
Brody School of Medicine at East Carolina UniversityClass of 1983
Certifications & Licensure
TX State Medical License 1993 - 2026
NY State Medical License 1992 - 1994
MD State Medical License 1986 - 1992
GA State Medical License 1984 - 1989- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Elected Member The American Society for Clinical Investigation, 2001
Clinical Trials
- Celecoxib as a Chemopreventive Agent in Current and Former Smokers Start of enrollment: 2001 Nov 01
Publications & Presentations
PubMed
- Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer.Nicolas Zhou, Cheuk H Leung, William N William Jr, Annikka Weissferdt, Apar Pataer
Journal for Immunotherapy of Cancer. 2024-10-23 - The cancer-associated secretory phenotype: a new frontier in targeted therapeutics.Xiaochao Tan, Guan-Yu Xiao, Priyam Banerjee, Shike Wang, Jonathan M Kurie
The Journal of Clinical Investigation. 2024-09-03 - Chromosomal 3q amplicon encodes essential regulators of secretory vesicles that drive secretory addiction in cancer.Xiaochao Tan, Shike Wang, Guan-Yu Xiao, Chao Wu, Xin Liu
The Journal of Clinical Investigation. 2024-04-25
Journal Articles
- JAK1/STAT3 Activation Through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung CancerJohn D Minna, Jonathan M Kurie, J Jack Lee, Vassiliki A Papadimitrakopoulou, Neda Kalhor, Roy S Herbst, Clinical Cancer Research
Press Mentions
MD Anderson Research Highlights for June 30, 2021June 30th, 2021- Novel Kras-Mutant Murine Models of Non-Small Cell Lung Cancer Possessing Co-Occurring Oncogenic Mutations and Increased Tumor Mutational BurdenJanuary 28th, 2021
Antiviral Treatments Lead Researchers to Develop Possible Cancer DrugJanuary 23rd, 2020- Join now to see all
Grant Support
- Regulation Of Lung Cancer Metastasis By Mir-200National Cancer Institute2011–2012
- Inflammation In Oncogenic K-Ras-Induced Lung TumorigenesisNational Cancer Institute2008–2012
- Kinase Signaling In Lung TumorigenesisNational Cancer Institute2004–2012
- P-3: Targeting Tumor Microenvironment In NsclcNational Cancer Institute2008–2011
- Mediators Of Oncogenic KRAS In Lung AdenocarcinomaNational Cancer Institute2006–2010
- Igfbp 6--A Target In Lung Cancer PreventionNational Cancer Institute2001–2006
- Retinoid Signaling In New Lung Cancer Prevention ModelsNational Cancer Institute2000–2005
- Trial Of Celecoxib In Lung Cancer ChemopreventionNational Cancer Institute2001–2002
- Retinoid Prevention Of Lung Cancer In Former SmokersNational Cancer Institute1996–2002
- Retinoid Signaling In Human Bronchial Epithelial CellNational Cancer Institute1995–1999
- Role Of FOS, Jun, RAR In Ra-Induced TC DifferentiationNational Cancer Institute1990–1992
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
